151. Leadless left ventricular endocardial pacing for cardiac resynchronization therapy: A systematic review and meta-analysis.
- Author
-
Wijesuriya N, Elliott MK, Mehta V, Sidhu BS, Behar JM, Niederer S, and Rinaldi CA
- Subjects
- Cardiac Resynchronization Therapy Devices, Endocardium, Heart Ventricles, Humans, Treatment Outcome, Ventricular Function, Left, Cardiac Resynchronization Therapy methods, Heart Failure diagnosis, Heart Failure therapy
- Abstract
Background: Leadless left ventricular (LV) endocardial pacing to achieve cardiac resynchronization therapy (CRT) is a novel procedure for treatment of patients with dyssynchronous heart failure. Current evidence is limited to observational studies with small patient numbers., Objective: The purpose of this systematic review and meta-analysis was to assess the safety and efficacy of leadless LV endocardial pacing., Methods: A literature search was conducted through PubMed, EMBASE, and Cochrane databases. Mean differences (MDs) in New York Heart Association (NYHA) functional class and LV ejection fraction (LVEF) from baseline to 6 months postprocedure were combined using a random effects model. Heterogeneity was evaluated using the Cochrane Q test, I
2 , meta-regression, and sensitivity analysis. Funnel plots were constructed to detect publication bias., Results: Five studies with 181 patients were included in the final analysis. Procedural success rate was 90.6%. Clinical response rate was 63%, with mean improvement in NYHA functional class of 0.43 (MD -0.43; 95% confidence interval [CI] -0.76 to -0.1; P = .01), with high heterogeneity (P <.001; I2 = 81.1%). There was a mean increase in LVEF of 6.3% (MD 6.3; 95% CI 4.35-8.19; P <.001, with low heterogeneity (P = 0.84; I2 <0.001%). The echocardiographic response rate was 54%. Procedure-related complication and mortality rates were 23.8% and 2.8%, respectively., Conclusion: The efficacy of leadless LV endocardial pacing for CRT supports its use as a second-line therapy in patients in whom standard CRT is not possible or has been ineffective. Improvements in safety profile will facilitate widespread uptake in the treatment of these patients., (Copyright © 2022 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF